Table 2.
Multivariable competing risks regression analysis after PSM of patients with metastatic prostate cancer, stratified according to treatment type (NLT vs LT).
| Variables | Local treatment versus no local treatment |
|
|---|---|---|
| HR (95% CI) | p value | |
| Type of treatment | ||
| No local therapy | Ref. | |
| Radiotherapy | 0.77 (0.63-0.95) | 0.01 |
| Radical prostatectomy | 0.36 (0.29-0.45) | <0.001 |
| Age (yr) | 1.00 (1.00-1.02) | 0.12 |
| Race | ||
| White | Ref. | |
| African American | 0.88 (0.71-1.07) | 0.20 |
| Other | 0.69 (0.49-0.97) | 0.03 |
| Year of diagnosis | ||
| 2004 | Ref. | |
| 2005 | 0.87 (0.59-1.28) | 0.47 |
| 2006 | 0.93 (0.62-1.38) | 0.72 |
| 2007 | 1.10 (0.73-1.66) | 0.65 |
| 2008 | 1.14 (0.78-1.67) | 0.51 |
| 2009 | 1.28 (0.87-1.86) | 0.21 |
| 2010 | 0.83 (0.47-1.45) | 0.51 |
| 2011 | 1.00 (0.58-1.73) | 0.99 |
| 2012 | 1.31 (0.69-2.47) | 0.41 |
| 2013 | 0.75 (0.41-1.39) | 0.36 |
| 2014 | 0.61 (0.34-1.11) | 0.11 |
| 2015 | 0.69 (0.38-1.25) | 0.22 |
| Gleason score | ||
| ≤6 | Ref. | |
| 7 | 1.42 (0.76-2.68) | 0.27 |
| ≥8 | 2.06 (1.12-3.80) | 0.02 |
| PSA | ||
| ≤20 | Ref. | |
| >20 | 1.38 (1.06-1.80) | 0.01 |
| AJCC.T | ||
| T1-T2 | Ref. | |
| T3-T4 | 1.64 (1.37-1.97) | <0.001 |
| AJCC.N | ||
| N0 | Ref. | |
| N1 | 1.43 (1.16-1.76) | <0.001 |
| AJCC.M | ||
| M1a | Ref. | |
| M1b | 1.90 (1.39-2.58) | <0.001 |
| M1c | 2.46 (1.76-3.43) | <0.001 |
| M1NOS | 2.85 (1.66-4.90) | <0.001 |
CI, confidence interval; HR, hazard ratio; Ref., reference;
AJCC, American Joint Committee on Cancer. The meaning of the bold values is p<0.05.